Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

58392

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sunbeds
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the Government plans to respond to the recommendations set out in the report of the All Party Parliamentary Group on Skin on sunbed regulation published in 2014.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199381
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The Government has noted the report and is currently considering how to respond to the recommendations<strong>.</strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 15:23:48 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58393

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the potential cost of extending the human papilloma virus vaccination programme to include all boys aged 12 and 13 years.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199382
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>We have not made any estimate of extending the human papillomavirus (HPV) vaccination programme to include boys aged 12 and 13 years, as the Joint Committee on Vaccination and Immunisation has not yet completed its consideration of whether HPV vaccine should be offered to males.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 14:44:56 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58394

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Alcoholic Drinks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the Government's assessment is of the effectiveness of warning labels on alcoholic beverages regarding drinking during pregnancy; and what assessment he has made of the potential benefits of making such labels mandatory.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199389
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>Research in the evidence around the effectiveness of alcohol harm reduction communications and related campaigns suggests that labelling and point of sale information can have an impact on consumption, in conjunction with broader campaigns to raise consumer awareness and education on the health risks linked to alcohol consumption.</p><p><strong> </strong></p><p>As part of the Public Health Responsibility Deal, alcohol retailers and producers have committed to putting an agreed warning or a pregnancy warning logo on 80% of labels on bottles and cans by the end of 2013. An independent market survey is underway to measure compliance. This level of coverage should allow the majority of consumers to see the pregnancy warning and logo.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 15:29:37 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58513

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199302
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199303 199304 question first answered 10/06/2014 15:28:08 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58515

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199303
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199304 question first answered 10/06/2014 15:28:10 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58516

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199304
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199303 question first answered 10/06/2014 15:28:11 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

57636

registered interest
date	04/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much the NHS has spent on treating (a) anal cancer, (b) penile cancer, (c) cervical cancer, (d) vaginal cancer, (e) vulval cancer, (f) oropharyngeal cancer, (g) genital warts and (h) recurrent respiratory papillomatosis in the last year.
tabling member constituency	Basildon and Billericay
tabling member printed	Mr John Baron
uin	198632
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>The Department does not collect National Health Service expenditure on treating individual cancers or other diagnoses. It does collect reference costs, which are the average unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given year to NHS patients.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/06/2014 15:48:30 answering member 3918 label Biography information for Jane Ellison
tabling member	1390 label Biography information for Mr John Baron

57696

registered interest
date	04/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Out of Area Treatment: Wales
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many patients resident in England but receiving health care in Wales have requested that their treatment be delivered in England in the last year.
tabling member constituency	Monmouth
tabling member printed	David T. C. Davies
uin	198553
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>This information is not held by the Department.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 198560 question first answered 11/06/2014 15:45:44 answering member 3918 label Biography information for Jane Ellison
tabling member	1545 label Biography information for David T C Davies

57697

registered interest
date	04/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Out of Area Treatment: Wales
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many patients resident in England have requested that their treatment be delivered in Wales in the last three years.
tabling member constituency	Monmouth
tabling member printed	David T. C. Davies
uin	198560
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>This information is not held by the Department.</p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 198553 question first answered 11/06/2014 15:45:44 answering member 3918 label Biography information for Jane Ellison
tabling member	1545 label Biography information for David T C Davies

57701

registered interest
date	04/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Abortion
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the Answer of 7 May 2014, Official Report, column 230W, on abortion, whether his Department has formed a view as to when the Royal college of Gynaecologists and Obstetricians publication, The Care of Women Requesting Induced Abortion, should be updated in order to take into account new research; and if he will make a statement.
tabling member constituency	Foyle
tabling member printed	Mark Durkan
uin	198620
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>An updated guideline, <em>The Care of Women Requesting Induced Abortion, </em>was published in 2011. The Royal College of Obstetricians and Gynaecologists is maintaining a watching brief on the needto review recommendations in the light of new research evidence.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/06/2014 15:53:26 answering member 3918 label Biography information for Jane Ellison attachment 1 file name Hansard Extract.docx title Hansard Extract
tabling member	1594 label Biography information for Mark Durkan